144 related articles for article (PubMed ID: 33449377)
1. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.
Abou Dalle I; Kantarjian HM; Ravandi F; Daver N; Wang X; Jabbour E; Estrov Z; DiNardo CD; Pemmaraju N; Ferrajoli A; Jain N; Wang SA; Jammal N; Borthakur G; Naqvi K; Pelletier S; Pierce S; Andreeff M; Garcia-Manero G; Cortes JE; Kadia TM
Cancer; 2021 Jun; 127(11):1894-1900. PubMed ID: 33449377
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
3. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
4. Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia.
O'Brien MM; Alonzo TA; Cooper TM; Levine JE; Brown PA; Slone T; August KJ; Benettaib B; Biserna N; Poon J; Patturajan M; Chen N; Simcock M; Zimmerman L; Kolb EA
Pediatr Blood Cancer; 2021 Jul; 68(7):e28946. PubMed ID: 33694257
[TBL] [Abstract][Full Text] [Related]
5. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.
Löwenberg B; Pabst T; Maertens J; Gradowska P; Biemond BJ; Spertini O; Vellenga E; Griskevicius L; Tick LW; Jongen-Lavrencic M; van Marwijk Kooy M; Vekemans MC; van der Velden WJFM; Beverloo B; Michaux L; Graux C; Deeren D; de Weerdt O; van Esser JWJ; Bargetzi M; Klein SK; Gadisseur A; Westerweel PE; Veelken H; Gregor M; Silzle T; van Lammeren-Venema D; Moors I; Breems DA; Hoogendoorn M; Legdeur MJC; Fischer T; Kuball J; Cornelissen J; Porkka K; Juliusson G; Meyer P; Höglund M; Gjertsen BT; Janssen JJWM; Huls G; Passweg J; Cloos J; Valk PJM; van Elssen CHMJ; Manz MG; Floisand Y; Ossenkoppele GJ
Blood Adv; 2021 Feb; 5(4):1110-1121. PubMed ID: 33616652
[TBL] [Abstract][Full Text] [Related]
6. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Ravandi F; Roboz GJ; Wei AH; Döhner H; Pocock C; Selleslag D; Montesinos P; Sayar H; Musso M; Figuera-Alvarez A; Safah H; Tse W; Sohn SK; Hiwase D; Chevassut T; Pierdomenico F; La Torre I; Skikne B; Bailey R; Zhong J; Beach CL; Dombret H
J Hematol Oncol; 2021 Aug; 14(1):133. PubMed ID: 34454540
[TBL] [Abstract][Full Text] [Related]
7. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH; Döhner H; Pocock C; Montesinos P; Afanasyev B; Dombret H; Ravandi F; Sayar H; Jang JH; Porkka K; Selleslag D; Sandhu I; Turgut M; Giai V; Ofran Y; Kizil Çakar M; Botelho de Sousa A; Rybka J; Frairia C; Borin L; Beltrami G; Čermák J; Ossenkoppele GJ; La Torre I; Skikne B; Kumar K; Dong Q; Beach CL; Roboz GJ;
N Engl J Med; 2020 Dec; 383(26):2526-2537. PubMed ID: 33369355
[TBL] [Abstract][Full Text] [Related]
8. Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.
Ferreri AJM; Sassone M; Angelillo P; Zaja F; Re A; Di Rocco A; Spina M; Fabbri A; Stelitano C; Frezzato M; Volpetti S; Zambello R; Rusconi C; De Lorenzo D; Scarano E; Arcari A; Bertoldero G; Nonis A; Calimeri T; Perrone S; Cecchetti C; Tarantino V; Steffanoni S; Foppoli M; Ciceri F; Ponzoni M
Hematol Oncol; 2020 Aug; 38(3):257-265. PubMed ID: 32356913
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.
Ferreri AJ; Sassone M; Zaja F; Re A; Spina M; Rocco AD; Fabbri A; Stelitano C; Frezzato M; Rusconi C; Zambello R; Couto S; Ren Y; Arcari A; Bertoldero G; Nonis A; Scarfò L; Calimeri T; Cecchetti C; Chiozzotto M; Govi S; Ponzoni M
Lancet Haematol; 2017 Mar; 4(3):e137-e146. PubMed ID: 28219694
[TBL] [Abstract][Full Text] [Related]
10. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
Wei A; Tan P; Perruzza S; Govindaraj C; Fleming S; McManus J; Avery S; Patil S; Stevenson W; Plebanski M; Spencer A
Br J Haematol; 2015 Apr; 169(2):199-210. PubMed ID: 25643589
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
Blum W; Klisovic RB; Becker H; Yang X; Rozewski DM; Phelps MA; Garzon R; Walker A; Chandler JC; Whitman SP; Curfman J; Liu S; Schaaf L; Mickle J; Kefauver C; Devine SM; Grever MR; Marcucci G; Byrd JC
J Clin Oncol; 2010 Nov; 28(33):4919-25. PubMed ID: 20956622
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.
Fehniger TA; Uy GL; Trinkaus K; Nelson AD; Demland J; Abboud CN; Cashen AF; Stockerl-Goldstein KE; Westervelt P; DiPersio JF; Vij R
Blood; 2011 Feb; 117(6):1828-33. PubMed ID: 21051557
[TBL] [Abstract][Full Text] [Related]
13. A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma.
Shea L; Watkins MP; Wan F; Cashen AF; Wagner-Johnston ND; Jacoby MA; Abboud CN; Dipersio JF; Hurd DD; Jaglowski SM; Bartlett NL; Fehniger TA
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2223-2228. PubMed ID: 32829079
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome.
Pham B; Hoeg R; Krishnan R; Richman C; Tuscano J; Abedi M
Bone Marrow Transplant; 2021 Dec; 56(12):2975-2980. PubMed ID: 34471239
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
[TBL] [Abstract][Full Text] [Related]
16. Phase Ib trial of lenalidomide as post-remission therapy for older adults with acute myeloid leukemia: Safety and longitudinal assessment of geriatric functional domains.
Woods JD; Zeidner JF; Van Deventer HW; Jamieson K; Matson M; Zhang J; Pulley W; Brenizer T; Muss H; Nyrop KA; Vohra SN; Deal AM; Ivanova A; Foster MC
J Geriatr Oncol; 2022 May; 13(4):499-504. PubMed ID: 34955443
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
Chen Y; Kantarjian H; Estrov Z; Faderl S; Ravandi F; Rey K; Cortes J; Borthakur G
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):341-4. PubMed ID: 22579233
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.
Merz LE; Perissinotti AJ; Marini BL; Burke PW; Crouch A; Erba HP; Bixby D
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):24-30. PubMed ID: 31711889
[TBL] [Abstract][Full Text] [Related]
19. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Saygin C; Larkin K; Blachly JS; Orwick S; Ngankeu A; Gregory CT; Phelps MA; Mani S; Walker A; Garzon R; Vasu S; Walsh KJ; Bhatnagar B; Klisovic RB; Grever MR; Marcucci G; Byrd JC; Blum W; Mims AS
Am J Hematol; 2020 Dec; 95(12):1457-1465. PubMed ID: 32777116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
